GSK plc (GSK) ORD GBP0.3125
9.50p
(0.52%)
- Add to watchlist
- Create an alert
- This stock can be held in a
9.50p
(0.52%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
9.50p
(0.52%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
GSK asthma treatment approved by US regulators
17 December 2025 07:05
(Sharecast News) - US regulators have approved GSK's Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ultra-long-acting biologic with twice-yearly dosing for this...
-
GSK secures MHRA nod for twice‑yearly respiratory treatment Exdensur
16 December 2025 07:53
(Sharecast News) - Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has received marketing authorisation from the UK's Medicines...
-
GSK gets preliminary nod for two respiratory drugs in Europe
12 December 2025 13:57
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use,...
-
GSK's Arexy receives EU green light
12 December 2025 07:20
(Sharecast News) - GSK said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended expanding the use of Arexy, its RSV vaccine, to all adults aged...
-
GSK's lung cancer drug granted orphan status by FDA
10 December 2025 07:18
(Sharecast News) - GSK's risvutatug rezetecan has received Orphan Drug Designation from US regulators for the treatment of small-cell lung cancer, the UK pharma group announced on Wednesday.
-
Berenberg raises target price on GSK
25 November 2025 09:22
(Sharecast News) - Analysts at Berenberg slightly raised their target price on drugmaker GSK from £16 to £16.60 per share on Tuesday after it hosted chief financial officer Julie Brown for the eighth...
-
GSK files suit against AnaptysBio over licensing rights
21 November 2025 07:02
(Sharecast News) - GSK has filed a lawsuit against AnaptysBio in the US over licensing rights for its Jemperli cancer treatment.
-
GSK posts better-than-expected Q3, upgrades guidance
29 October 2025 07:20
(Sharecast News) - GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by robust growth in specialty medicines and steady contributions from...
-
GSK lung cancer treatment gets EU orphan drug status
28 October 2025 07:14
(Sharecast News) - GSK on Tuesday said its treatment for small-cell lung cancer (SCLC) had received orphan drug status from the European Medicines Agency.
-
GSK shares lift on £268m prostate cancer deal
27 October 2025 09:33
(Sharecast News) - GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.
-
GSK's Blenrep receives US FDA approval
24 October 2025 07:03
(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration had approved its Blenrep asset in combination with bortezomib and dexamethasone for the treatment of adults with...
-
GSK advances low-carbon inhaler, halts latozinemab study after mixed data
22 October 2025 08:12
(Sharecast News) - Drugmaker GSK released two sets of trial data on Wednesday, covering its low-carbon asthma inhaler and a potential new treatment for multiple sclerosis.
Company announcements Announcements
-
Transaction in Own Shares
19 December 2025 07:00
GSK
-
Transaction in Own Shares
18 December 2025 07:00
GSK
-
Exdensur (depemokimab ulla) approved by US FDA
17 December 2025 07:00
GSK
-
Transaction in Own Shares
17 December 2025 07:00
GSK
-
Exdensur (depemokimab) UK MHRA approval
16 December 2025 07:00
GSK
-
Transaction in Own Shares
16 December 2025 07:00
GSK
-
Transaction in Own Shares
15 December 2025 07:00
GSK
-
Nucala receives positive CHMP opinion for COPD
12 December 2025 13:50
GSK
-
Depemokimab receives positive CHMP opinion
12 December 2025 13:41
GSK
-
Positive CHMP opinion on Arexvy for all adults 18+
12 December 2025 07:00
GSK
-
Transaction in Own Shares
12 December 2025 07:00
GSK
-
Blujepa approved in US for gonorrhoea indication
11 December 2025 17:54
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.